The U.S. company formally kicked off the bid for its peer across the northern border.

Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.

Curaleaf (CURA.TO)on Tuesday formally launched its unsolicited takeover bid for Aurora Cannabis (ACB

Curaleaf Holdings has delivered a sharp 70.0% share price decline over the past five years, yet the stock still screens as cheap on several valuation checks. This puts recent news around expansion plans under a brighter spotlight for investors trying to judge whether today’s price is attractive. The 70.0% drop over five years suggests investors have already priced in a lot of sector and company specific challenges, so any recovery case now starts from a much lower base. Curaleaf’s push to...

Cannabis consolidation appears to be accelerating.

Curaleaf CEO Boris Jordan says he tried to play nice before taking its $4-per-share Aurora bid public. “We wanted to be friendly,” he said in an exclusive interview.

Curaleaf is attempting to acquire Canopy Growth's rival, Aurora Cannabis, and there could be more consolidation to come in the industry.

Aurora Cannabis would expand Curaleaf's international presence, but it hasn't been a strong business in recent years.

Aurora Cannabis shares rally as Curaleaf announces plans of an unsolicited takeover bid. Here’s what the development means for ACB shares.

German market expansion drove $43M in international medical cannabis revenue amid Canadian pricing pressure.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Canada-based Aurora is reviewing an unsolicited offer from cannabis company Curaleaf to be taken over for about $272 million.

(Updates with Aurora Cannabis' response in the fifth, sixth and seventh paragraphs and updates share

Curaleaf Hldgs Inc. (OTCQX:CURLF) has launched a hostile bid to acquire Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB), offering Aurora shareholders a combination of Curaleaf shares and cash that values the proposal at US$4 per Aurora share, as it seeks to combine the companies’ international...

Curaleaf announced a cash-and-stock offer that represents a 45% premium to Aurora’s 30-day volume-weighted average price.

In a strategic bid to forge a global cannabis powerhouse, Curaleaf Holdings (TSX:CURA) unveiled its intention to launch a takeover bid for Aurora Cannabis (TSX/NASDAQ:ACB). The proposed offer values Aurora at US$4 per share —reflecting a 45% premium over its 30-day volume-weighted average price (VWAP)— with potential upside capped at US$5 per share (an 82% premium) under a structured cash-and-stock arrangement.

Investors are on edge ahead of the release of July CPI data tomorrow

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Read Exec Edge’s Initiation on ACB Here Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com [email protected] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests – Downloadable Quarterly Update Report appeared first on ExecEdge.

Aurora Cannabis (NASDAQ:ACB) said shareholders approved all items presented at its annual general meeting, including setting the board size at five directors, electing the company’s nominees, reappointing Ernst & Young LLP as auditor, and approving its non-binding advisory vote on executive comp

International medical cannabis revenue surged 17% to CAD43 million, offsetting Canadian reimbursement cuts and positioning Aurora for continued global expansion.

Aurora Cannabis (ACB) delivered earnings and revenue surprises of +130.77% and +4.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (NASDAQ:ACB) reported fiscal first-quarter 2027 net revenue of C$67.6 million, as growth in international medical cannabis sales was offset by lower Canadian medical revenue following reimbursement changes and the company’s planned exit from lower-margin Canadian consumer cannabis op

Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.

Key Takeaways; Cannabis Sector Trulieve and Green Thumb were Named Among TIME’s America’s Best Companies of 2026 Curaleaf Holdings Options Set to Begin Trading on Montréal Exchange Aurora Cannabis Earned TIME Canada Recognition, As the Company Announced Plans to Strengthen Governance Ahead of Annual Meeting Key Takeaways; Psychedelic Sector Compass Pathways Strengthened Case for FDA […]

Moby summary of Aurora Cannabis Inc.'s Q4 2026 earnings call